Amir S. Yazdi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amir S. Yazdi has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Gerda Wurpts
Department of Dermatology and Allergy Uniklinik RWTH Aachen Aachen Germany
2 shared publications- Kamran Ghoreschi
Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
2 shared publications - Martin Röcken
Department of Dermatology, Eberhard Karls University, Tübingen, Germany
2 shared publications Stefanie Müller
2 shared publicationsAlbert Sickmann
Leibniz-Institute for Analytical Sciences (ISAS) e.V., Dortmund, Germany
1 shared publicationAmol Fatangare
Leibniz-Institute for Analytical Sciences (ISAS) e.V., Dortmund, Germany
1 shared publication
Latest Publications
- 21 September 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Evaluation of suspected delayed‐type allergy to beta‐lactam antibiotics: a 6‐year retrospective single center experience
Summary: Background and objectives: As allergies against beta‐lactam antibiotics (BLA) are among the most common drug allergies, diagnostic testing is essential when an allergic reaction is suspected. To investigate the outcomes of allergy testing in patients with delayed‐type allergy to BLA. Patients and methods: The prevalence of delayed‐type allergy to aminopenicillins or other BLA as well as their cross‐reactivity, were analyzed by using skin testing (patch, prick, intradermal tests) and drug challenge testing (DCT). Results: Aminopenicillins were the most frequently suspected culprit drugs in the evaluated cohort (n = 487), and delayed‐type allergy was confirmed in 29.9% of patients. DCT was positive despite negative skin test results in 6.0% (29/487). Cross reactivity with closely related BLA groups were found in 10% (8/80) of patients. Given that 88.9% (297/334) of patients with previous negative skin test results tolerated the subsequent drug challenge without allergic reaction, the negative predictive value of skin testing appears reliable within a standardized clinical setting. Conclusions: Thorough allergy diagnostic testing prevents re‐exposure to culprit drugs and enables the delabeling of patients with suspected drug allergy, thereby avoiding unnecessary treatment restrictions. Allergy testing is therefore an important and effective component of the diagnostic workup following a history of maculopapular exanthema.
- 21 September 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Evaluation of suspected delayed‐type allergy to beta‐lactam antibiotics: a 6‐year retrospective single center experience
Summary: Background and objectives: As allergies against beta‐lactam antibiotics (BLA) are among the most common drug allergies, diagnostic testing is essential when an allergic reaction is suspected. To investigate the outcomes of allergy testing in patients with delayed‐type allergy to BLA. Patients and methods: The prevalence of delayed‐type allergy to aminopenicillins or other BLA as well as their cross‐reactivity, were analyzed by using skin testing (patch, prick, intradermal tests) and drug challenge testing (DCT). Results: Aminopenicillins were the most frequently suspected culprit drugs in the evaluated cohort (n = 487), and delayed‐type allergy was confirmed in 29.9% of patients. DCT was positive despite negative skin test results in 6.0% (29/487). Cross reactivity with closely related BLA groups were found in 10% (8/80) of patients. Given that 88.9% (297/334) of patients with previous negative skin test results tolerated the subsequent drug challenge without allergic reaction, the negative predictive value of skin testing appears reliable within a standardized clinical setting. Conclusions: Thorough allergy diagnostic testing prevents re‐exposure to culprit drugs and enables the delabeling of patients with suspected drug allergy, thereby avoiding unnecessary treatment restrictions. Allergy testing is therefore an important and effective component of the diagnostic workup following a history of maculopapular exanthema.
- Open Access
- 11 January 2025
- Published by Elsevier in Allergology International
- Vol. 74 (3) , 414-423
Analysis of differential gene expression of PBMC for the in vitro detection of drug sensitization
- 11 January 2025
- Published by Elsevier in Allergology International
- Vol. 74 (3) , 414-423
Open AccessAnalysis of differential gene expression of PBMC for the in vitro detection of drug sensitization
- 15 September 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (2) , 263-272.e8
Type 2 T-Cell Responses against Distinct Epitopes of the Desmoglein 3 Ectodomain in Pemphigus Vulgaris
- 15 September 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (2) , 263-272.e8
Type 2 T-Cell Responses against Distinct Epitopes of the Desmoglein 3 Ectodomain in Pemphigus Vulgaris
- 2 May 2023
- Published by Morressier GmbH
ISID0123 - ATF3 distinguishes between innate and adaptive immunity
- 2 May 2023
- Published by Morressier GmbH
ISID0123 - ATF3 distinguishes between innate and adaptive immunity
- 9 August 2022
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 164 (14) , 9
Sudden vein drawing after antibiotic administration
- 9 August 2022
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 164 (14) , 9
Sudden vein drawing after antibiotic administration
- Open Access
- 17 May 2021
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 118 (19-20) , 338
Intolerance Reaction After Vaccination Against SARS-CoV-2
- 17 May 2021
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 118 (19-20) , 338
Open AccessIntolerance Reaction After Vaccination Against SARS-CoV-2
- 1 September 2017
- Published by Elsevier in Journal of Dermatological Science
- Vol. 87 (3) , 246-251
Differential induction of ATF3 and HO-1 in myeloid cells and keratinocytes via Dimethylfumarate or Cyclosporine A
- 1 September 2017
- Published by Elsevier in Journal of Dermatological Science
- Vol. 87 (3) , 246-251
Differential induction of ATF3 and HO-1 in myeloid cells and keratinocytes via Dimethylfumarate or Cyclosporine A
- 7 July 2010
- Published by PERSEE Program
- Vol. 20 (5) , 575-9
Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation.
BRAF exon 15 mutations have been identified in a large proportion of malignant melanomas, melanoma metastases and melanocytic nevi. Mutated BRAF is one of the potential activators of the mitogen-activated protein kinase (MAPK) signaling pathway by phosphorylating ERK (extracellular signal-regulated kinase). We therefore analyzed the correlation of BRAF V600E and ERK-activation in 20 malignant melanomas and 21 subsequently evolved, paired metastases of the same donor by BRAF exon 15 DNA sequencing and phospho-specific immunohistochemistry for ERK. Phospho-ERK expression was present in 84% of primary melanomas and in all 19 metastases analyzed. In contrast, BRAF mutational status was concordant in only 12/20 pairs (60%) of the primary melanoma and metastasis of the same patient. Surprisingly, the BRAF mutation did not correlate with pERK expression. As even single tumors showed heterogeneous staining for pERK, we used laser-capture microdissection to study BRAF V600E status in pERK positive and pERK negative cells separately. Even on the single cell level ERK activation did not correlate with the BRAF mutation. Our results demonstrate that, in melanomas, activation of the MAPK pathway can occur through signaling pathways operating independently of BRAF T1799A.
- 7 July 2010
- Published by PERSEE Program
- Vol. 20 (5) , 575-9
Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation.
BRAF exon 15 mutations have been identified in a large proportion of malignant melanomas, melanoma metastases and melanocytic nevi. Mutated BRAF is one of the potential activators of the mitogen-activated protein kinase (MAPK) signaling pathway by phosphorylating ERK (extracellular signal-regulated kinase). We therefore analyzed the correlation of BRAF V600E and ERK-activation in 20 malignant melanomas and 21 subsequently evolved, paired metastases of the same donor by BRAF exon 15 DNA sequencing and phospho-specific immunohistochemistry for ERK. Phospho-ERK expression was present in 84% of primary melanomas and in all 19 metastases analyzed. In contrast, BRAF mutational status was concordant in only 12/20 pairs (60%) of the primary melanoma and metastasis of the same patient. Surprisingly, the BRAF mutation did not correlate with pERK expression. As even single tumors showed heterogeneous staining for pERK, we used laser-capture microdissection to study BRAF V600E status in pERK positive and pERK negative cells separately. Even on the single cell level ERK activation did not correlate with the BRAF mutation. Our results demonstrate that, in melanomas, activation of the MAPK pathway can occur through signaling pathways operating independently of BRAF T1799A.
- 1 September 2007
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 143 (9) , 1209-1226
Lymphomatoid Granulomatosis Induced by Imatinib-Treatment
An 89-year-old woman with liver metastases from a gastrointestinal stromal tumor (GIST) was treated with imatinib mesylate, initial dose of 400 mg/d. Three mont
- 1 September 2007
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 143 (9) , 1209-1226
Lymphomatoid Granulomatosis Induced by Imatinib-Treatment
An 89-year-old woman with liver metastases from a gastrointestinal stromal tumor (GIST) was treated with imatinib mesylate, initial dose of 400 mg/d. Three mont